SCENESSE 16 mg implant
CUV052
Phase 2 small_molecule active
Quick answer
SCENESSE 16 mg implant for Erythropoietic Protoporphyria (EPP) is a Phase 2 program (small_molecule) at Clinuvel Europe Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Clinuvel Europe Limited
- Indication
- Erythropoietic Protoporphyria (EPP)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active